Biblio
Export 957 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is F [Clear All Filters]
“Effect of a Comprehensive Intervention on Plasma BDNF in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 57, no. 1, pp. 37-43, 2017.
, “Effect of a Comprehensive Intervention on Plasma BDNF in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 57, no. 1, pp. 37-43, 2017.
, “Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1293-1302, 2017.
, “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
, “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
, “The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.”, J Alzheimers Dis, vol. 56, no. 2, pp. 805-815, 2017.
, “Effects of Multiple Genetic Loci on Age at Onset in Frontotemporal Dementia.”, J Alzheimers Dis, vol. 56, no. 4, pp. 1271-1278, 2017.
, “Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1325-1334, 2017.
, “Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 57, no. 2, pp. 387-393, 2017.
, “Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 57, no. 2, pp. 387-393, 2017.
, “Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1583-1594, 2017.
, “Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1583-1594, 2017.
, “Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.”, J Alzheimers Dis, vol. 56, no. 1, pp. 129-143, 2017.
, “The Efficacy of Emotion Recognition Rehabilitation for People with Alzheimer's Disease.”, J Alzheimers Dis, vol. 57, no. 3, pp. 937-951, 2017.
, “Episodic Memory Dysfunction in Behavioral Variant Frontotemporal Dementia: A Clinical And FDG-PET Study.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1251-1264, 2017.
, “Evaluation of a DNA Aβ42 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA Aβ42 Trimer.”, J Alzheimers Dis, vol. 57, no. 1, pp. 97-112, 2017.
, “Face-Name Associative Recognition Deficits in Subjective Cognitive Decline and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 56, no. 3, pp. 1185-1196, 2017.
, “Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1489-1496, 2017.
, “Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1489-1496, 2017.
, “Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia.”, J Alzheimers Dis, vol. 59, no. 1, pp. 67-75, 2017.
, “Functional Disintegration of the Default Mode Network in Prodromal Alzheimer's Disease.”, J Alzheimers Dis, vol. 59, no. 1, pp. 169-187, 2017.
, “Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid-β Peptide 1-37 (Aβ37).”, J Alzheimers Dis, vol. 57, no. 1, pp. 135-145, 2017.
, “Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid-β Peptide 1-37 (Aβ37).”, J Alzheimers Dis, vol. 57, no. 1, pp. 135-145, 2017.
, “Genetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral Neuropathy.”, J Alzheimers Dis, vol. 55, no. 1, pp. 249-258, 2017.
, “Genetic Prion Disease Caused by PRNP Q160X Mutation Presenting with an Orbitofrontal Syndrome, Cyclic Diarrhea, and Peripheral Neuropathy.”, J Alzheimers Dis, vol. 55, no. 1, pp. 249-258, 2017.
,